Placebo to veliparib

DRUG2 trials

Sponsors

AbbVie

Conditions

Ovarian CancerOvarian NeoplasmSquamous Non-Small Cell Lung Cancer

Phase 3

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

CompletedNCT02106546

AbbVieSquamous Non-Small Cell Lung Cancer

Start: 2014-04-10End: 2019-11-20Updated: 2020-11-17

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

TerminatedNCT02470585

AbbVieOvarian Cancer, Ovarian Neoplasm

Start: 2015-07-14End: 2023-10-05Updated: 2024-10-26

Related Papers

Quality-adjusted progression-free survival analysis of veliparib and carboplatin/paclitaxel compared with chemotherapy alone in patients with newly diagnosed ovarian cancer (VELIA/GOG3005): ancillary analysis of a placebo-controlled, phase 3 randomized trial.

2025-11-21

Folate receptor alpha (FRα; FOLR1) expression and persistence in ovarian cancer in clinical trial samples and real-world patient cohort.

Journal of Clinical Oncology2025-05-281 citations

Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial.

2023-04-018 citations

Multidisciplinary considerations in the maintenance treatment of poly(ADP‐ribose) polymerase inhibitors for homologous recombination‐proficient, advanced‐stage epithelial ovarian cancer

CA A Cancer Journal for Clinicians2022-11-1110 citations

Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer.

2022-03-028 citations

Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.

2021-12-1813 citations

Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.

2021-12-1130 citations

Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study

Journal of Clinical Oncology2021-08-2648 citations

16 Quality-adjusted (QA) progression-free survival analyses of veliparib + carboplatin/paclitaxel (CP) vs CP alone in patients with newly diagnosed ovarian cancer

2020-11-011 citations

PFS by blinded independent central review (BICR) in the VELIA trial of veliparib (V) plus carboplatin/paclitaxel (CP) and as monotherapy in newly diagnosed patients (pts) with high-grade serous ovarian cancer (HGSC).

Journal of Clinical Oncology2020-05-202 citations

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

New England Journal of Medicine2019-09-28885 citations

A phase I study of veliparib incorporated into front-line platinum based cheotherpy and bevacizumab in epithelial ovarian cancer (NCT00989651): A GOG/nrg trial.

Journal of Clinical Oncology2019-05-206 citations

Phase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors

Cancer Science2017-06-3024 citations

Veliparib (ABT-888) or placebo combined with carboplatin and paclitaxel in patients with previously untreated advanced/metastatic squamous (Sq) non-small cell lung cancer (NSCLC): A randomized phase 3 trial.

Journal of Clinical Oncology2015-05-203 citations